Company intelligence / Profile preview
X4 Pharmaceuticals, Inc.
Boston, Massachusetts, United States of Americax4pharma.com ↗
- Ownership
- Public · XFOR
- Employees
- ~143
- Development stage
- Other
01
Overview
X4 Pharmaceuticals received FDA approval for XOLREMDI™ (Mavorixafor) on April 26, 2024, for treating patients aged 12 and older with WHIM syndrome to increase mature neutrophils and lymphocytes in circulation. The company reported Q1 2025 financial results on May 1, 2025, and announced a strategic restructuring on February 6, 2025.
- Therapeutic areas
- HematologyImmunologyInfectious Diseases
- Modalities
- Small molecule drugsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Hercules Capital (financing partner)
04
Financials
- Market cap
- $304.4M
- Total revenue
- $35.1M
- Enterprise value
- $116.9M
Beyond the preview
Go deeper on X4 Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on X4 Pharmaceuticals, Inc..